Urethral Neoplasms: Clinical Trials

58 trials for Urethral Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

37 completed, 9 terminated, 7 active not recruiting, 3 recruiting. 58 Phase 2, 4 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 258Completed 37, Terminated 9, Active not recruiting 7, Recruiting 3, Unknown 1, Withdrawn 1
Phase 14Completed 2, Recruiting 1, Terminated 1
Phase 31Completed 1

Follow Urethral Neoplasms: new trials by email Literature Review of Urethral Neoplasms trials Research Report on Urethral Neoplasms

Trials (filtered) newest first · largest first

All 58 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Trial of AM80 in Combination With Gemcitabine, Cisplatin, and Nivolumab in Patients With Urothelial Carcinoma
Add-on effect of adding tamivarotene (AM80) to gemcitabine, cisplatin, and nivolumab combination therapy - Urothelial Carcinoma Bladder, Urothelial Carcinoma of the Renal Pelvis and Ureter
Phase 2RecruitingNagoya University432025-05-012025-08-14
Agnostic Therapy in Rare Solid Tumors
Nivolumab - Urachal Cancer, Parathyroid Carcinoma
Phase 2Active not recruitingInstituto do Cancer do Estado de São Paulo282024-07-162026-10-13
64Cu-GRIP B in Patients With Advanced Malignancies
Copper-64 labeled Granzyme B (64Cu-GRIP B), Positron Emission Tomography (PET) - Prostate Cancer, Renal Cancer
Phase 1 / Phase 2RecruitingRahul Aggarwal912023-05-252026-03-17
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
Ipilimumab, Nivolumab, Tocilizumab - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
Phase 2Active not recruitingM.D. Anderson Cancer Center352021-09-232026-09-16
ARID1A and/or KDM6A Mutation and CXCL13 Expression
Diagnostic Laboratory Biomarker Analysis, Nivolumab, Relatlimab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Phase 2Active not recruitingM.D. Anderson Cancer Center62021-09-212026-10-06
Immune Checkpoint Inhibitors With or Without Propranolol Hydrochloride In Patients With Urothelial Carcinoma
Pembrolizumab, Propranolol Hydrochloride, Nivolumab - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Phase 2Active not recruitingEmory University62021-05-202026-02-19
Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma
Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)472019-06-052024-07-26
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Biospecimen Collection, Bone Scan, Cabozantinib S-malate - Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Phase 2RecruitingNational Cancer Institute (NCI)3142019-05-132026-11-12
Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer
Avelumab, Cisplatin, Fluorouracil - Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage II Bladder Cancer AJCC v8
Phase 2CompletedMayo Clinic22018-09-192023-01-06
Atezolizumab With or Without Eribulin Mesylate in Treating Patients With Recurrent Locally Advanced or Metastatic Urothelial Cancer
Atezolizumab, Biopsy Procedure, Biospecimen Collection - Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)722018-07-202026-11-12
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Rucaparib - Bladder Cancer, Urothelial Carcinoma
Phase 2Terminatedpharmaand GmbH972018-06-012023-06-09
Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma
Atezolizumab, Guadecitabine - Urothelial Carcinoma
Phase 2Active not recruitingFox Chase Cancer Center212017-11-272021-11-04
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
enfortumab vedotin (EV), pembrolizumab, cisplatin - Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
Phase 1 / Phase 2TerminatedAstellas Pharma Global Development, Inc.3482017-10-112026-03-24
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
Enfortumab vedotin - Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
Phase 2CompletedAstellas Pharma Inc2192017-10-082024-08-27
Afatinib in Advanced Refractory Urothelial Cancer
afatinib dimaleate, laboratory biomarker analysis - Distal Urethral Cancer, Proximal Urethral Cancer
Phase 2TerminatedUniversity of Chicago322017-09-132025-04-25
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
Crizotinib - Urinary Bladder Neoplasms, Ureteral Neoplasms
Phase 2TerminatedWake Forest University Health Sciences82016-09-272022-11-03
Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery
Eribulin Mesylate, Gemcitabine Hydrochloride - Metastatic Ureter Carcinoma, Metastatic Urethral Carcinoma
Phase 2CompletedNational Cancer Institute (NCI)262014-12-112019-12-16
A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function
Vinflunine, Gemcitabine, Carboplatin - Urothelial Carcinoma, Bladder Cancer
Phase 2CompletedDr Anders Ullén622014-04-012019-10-08
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer
cisplatin, gemcitabine hydrochloride, methotrexate - Anterior Urethral Cancer, Localized Transitional Cell Cancer of the Renal Pelvis and Ureter
Phase 2WithdrawnUniversity of Southern California2013-05-012014-01-29
Cabozantinib for Advanced Urothelial Cancer
Cabozantinib - Urothelial Carcinoma, Urethral Neoplasms
Phase 2CompletedNational Cancer Institute (NCI)692012-09-112022-10-18

Showing 20 of 58. Sign in to see all of them.

Narrower conditions

Urinary Bladder Neoplasms (53)  ·  Ureteral Neoplasms (25)  ·  Carcinoma, Transitional Cell (13)  ·  Carcinoma, Renal Cell (2)  ·  Kidney Neoplasms (2)  ·  Neoplasms (2)  ·  Penile Neoplasms (2)  ·  Prostatic Neoplasms (2)  ·  Urachal adenocarcinoma (2)  ·  Urachal cancer (2)  ·  Urologic Neoplasms (2)  ·  Adrenal Gland Neoplasms (1)  ·  Anus Neoplasms (1)  ·  Biliary Tract Neoplasms (1)

Broader conditions

Female Urogenital Diseases (58)  ·  Female Urogenital Diseases and Pregnancy Complications (58)  ·  Male Urogenital Diseases (58)  ·  Urethral Diseases (58)  ·  Urogenital Diseases (58)  ·  Urologic Diseases (58)  ·  Neoplasms by Site (57)  ·  Urogenital Neoplasms (57)  ·  Neoplasms (56)  ·  Urologic Neoplasms (56)  ·  Urinary Bladder Diseases (53)  ·  Ureteral Diseases (25)  ·  Neoplasms by Histologic Type (16)  ·  Carcinoma (15)  ·  Neoplasms, Glandular and Epithelial (15)

Interventions

Gemcitabine (19)  ·  Cisplatin (12)  ·  Carboplatin (6)  ·  Paclitaxel (6)  ·  Nivolumab (5)  ·  Fluorouracil (4)  ·  Doxorubicin (3)  ·  Magnetic Resonance Spectroscopy (3)  ·  Radiotherapy (3)  ·  Specimen Handling (3)  ·  Sunitinib (3)  ·  atezolizumab (3)  ·  Biopsy (2)  ·  CTLA-4 Antigen (2)  ·  Docetaxel (2)

Sponsors

National Cancer Institute (NCI) (12)  ·  M.D. Anderson Cancer Center (6)  ·  SWOG Cancer Research Network (6)  ·  Eastern Cooperative Oncology Group (4)  ·  Cardiff University (3)  ·  European Organisation for Research and Treatment of Cancer - EORTC (3)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  Achieve Life Sciences (1)  ·  Altor BioScience (1)  ·  Astellas Pharma Global Development, Inc. (1)  ·  Astellas Pharma Inc (1)  ·  AstraZeneca (1)  ·  Dendreon (1)  ·  Dr Anders Ullén (1)  ·  Eli Lilly and Company (1)

Countries

United States (42)  ·  Spain (7)  ·  United Kingdom (7)  ·  Italy (6)  ·  Canada (5)  ·  France (5)  ·  Netherlands (5)  ·  Germany (4)  ·  Puerto Rico (3)  ·  South Africa (3)  ·  Belgium (2)  ·  Brazil (2)  ·  Denmark (2)  ·  Israel (2)  ·  Japan (2)

Top investigators

Daniel P. Petrylak, MD (2)  ·  Dean F. Bajorin, MD (2)  ·  Robert Dreicer (2)  ·  Robert Dreicer, MD, FACP (2)  ·  Andrea B Apolo (1)  ·  Andrea B Apolo, M.D. (1)  ·  Andrea Necchi, MD (1)  ·  Anishka A D'Souza (1)  ·  Arif Hussain (1)  ·  Arlene Siefker-Radtke (1)  ·  Arlene Siefker-Radtke, MD (1)  ·  Bruce J. Roth, MD (1)  ·  Camila MV Moniz, Doctor (1)

Results publications

PMID 12448661, PMID 12767086, PMID 15911238, PMID 18459175, PMID 18501081, PMID 19269798, PMID 19371909, PMID 19786668, PMID 22162575, PMID 22819172, PMID 23329066, PMID 25427282, PMID 26149529, PMID 26582660, PMID 26926681, PMID 31356140, PMID 31390274, PMID 31648851, PMID 32645282, PMID 33991512, PMID 34030643, PMID 35031545, PMID 35168844, PMID 35537412, PMID 36041086, PMID 37328287, PMID 37369081, PMID 38215355, PMID 38849479

NIH funding

U10CA032102 (6), U10CA031946 (3), U10CA021115 (2), 2017 (1), N01CM00038 (1), N01CM62201 (1), N01CM62205 (1), N01CM62209 (1), P30CA014599 (1), P30CA015704 (1), P30CA016672 (1), P30CA093373 (1), P30CA138292 (1), P50CA091846 (1), R01CA229354 (1)